vice president business development 21/5/13, page-11

Perhaps a reorganisation of positions and duties? Is this to be Hugh Alsop's replacement, but based in the US as perhaps now required with clinical trials set to take place there?

Also intriguing is the mention of 3 non-opioid pain products in development, seemingly in addition to diclofenac gel. POH's pipeline is becoming positively jam-packed with projects.

This means that under development now will be:

1) transdermal oxycodone patch
2) topical oxycodone patch
3) transdermal oxymorphone patch
4) new transdermal opioid? (or so we've heard?)
5) novel diclofenac formulation with Nippon Zoki (patch?
aerosol?)
6) lidocaine? (seems this might be back on the table as
second non-opioid pain product)
7) ??? (third non-opiod pain product)

8) topical retinoic acid
9) topical ketoconazole

10)injectable antibiotic

11)bovine mastitis
12)further horse supplements

And then, of course, there's ongoing product development in the cosmetic area.

The wording of the job description suggests that this person might only be overseeing the pain products in development, but that would still involve 6 or 7 different products.

Wow...this is becoming seriously busy.